Repositório Digital

A- A A+

Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil : a national survey

.

Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil : a national survey

Mostrar registro completo

Estatísticas

Título Detection of Helicobacter pylori resistance to clarithromycin and fluoroquinolones in Brazil : a national survey
Autor Sanches, Bruno Squárcio Fernandes
Martins, Gustavo Miranda
Lima, Karine Sampaio
Cota, Bianca Della Croce Vieira
Moretzsohn, Luciana Dias
Ribeiro, Laércio Tenório
Breyer, Helenice Pankowski
Maguilnik, Ismael
Maia, Alinne Lais Bessa
Rezende Filho, Joffre
Meira, Ana Carolina
Pinto, Henrique
Alves, Edson J.
Mascarenhas, Ramiro Robson Fernandes
Passos, Raissa Iglesias Fernandes Angelo
Souza, Julia Duarte de
Trindade, Osmar Reni
Coelho, Luiz Gonzaga Vaz
Abstract AIM To evaluate bacterial resistance to clarithromycin and fluoroquinolones in Brazil using molecular methods. METHODS The primary antibiotic resistance rates of Helicobacter pylori (H. pylori) were determined from November 2012 to March 2015 in the Southern, South-Eastern, Northern, North-Eastern, and Central-Western regions of Brazil. Four hundred ninety H. pylori patients [66% female, mean age 43 years (range: 18-79)] who had never been previously treated for this infection were enrolled. All patients underwent gastroscopy with antrum and corpus biopsies and molecular testing using GenoType HelicoDR (Hain Life Science, Germany). This test was performed to detect the presence of H. pylori and to identify point mutations in the genes responsible for clarithromycin and fluoroquinolone resistance. The molecular procedure was divided into three steps: DNA extraction from the biopsies, multiplex amplification, and reverse hybridization. RESULTS Clarithromycin resistance was found in 83 (16.9%) patients, and fluoroquinolone resistance was found in 66 (13.5%) patients. There was no statistical difference in resistance to either clarithromycin or fluoroquinolones (p = 0.55 and p = 0.06, respectively) among the different regions of Brazil. Dual resistance to clarithromycin and fluoroquinolones was found in 4.3% (21/490) of patients. The A2147G mutation was present in 90.4% (75/83), A2146G in 16.9% (14/83) and A2146C in 3.6% (3/83) of clarithromycin-resistant patients. In 10.8% (9/83) of clarithromycin-resistant samples, more than 01 mutation in the 23S rRNA gene was noticed. In fluoroquinolone-resistant samples, 37.9% (25/66) showed mutations not specified by the GenoType HelicoDR test. D91N mutation was observed in 34.8% (23/66), D91G in 18.1% (12/66), N87K in 16.6% (11/66) and D91Y in 13.6% (9/66) of cases. Among fluoroquinolone-resistant samples, 37.9% (25/66) showed mutations not specified by the GenoType HelicoDR test. CONCLUSION The H. pylori clarithromycin resis­tance rate in Brazil is at the borderline (15%-20%) for applying the standard triple therapy. The fluoroqui­nolone resistance rate (13.5%) is equally concerning.
Contido em World journal of gastroenterology. Beijing. Vol. 22, no. 33 (Sept. 7, 2016), p. 7587-7594
Assunto Antibacterianos
Claritromicina
Farmacorresistência bacteriana
Fluoroquinolonas
Infecções por Helicobacter
Testes de sensibilidade microbiana
[en] Clarithromycin
[en] Fluoroquinolones
[en] Helicobacter pylori
[en] Microbial drug resistence
[en] Molecular diagnostic techniques
Origem Estrangeiro
Tipo Artigo de periódico
URI http://hdl.handle.net/10183/168881
Arquivos Descrição Formato
001047703.pdf (893.8Kb) Texto completo (inglês) Adobe PDF Visualizar/abrir

Este item está licenciado na Creative Commons License

Este item aparece na(s) seguinte(s) coleção(ões)


Mostrar registro completo

Percorrer



  • O autor é titular dos direitos autorais dos documentos disponíveis neste repositório e é vedada, nos termos da lei, a comercialização de qualquer espécie sem sua autorização prévia.
    Projeto gráfico elaborado pelo Caixola - Clube de Criação Fabico/UFRGS Powered by DSpace software, Version 1.8.1.